title: Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: I. Expression and role of cytochromes P450.
abstract: Cutaneous drug reactions (CDRs) are among the most common adverse drug reactions and are responsible for numerous minor to life-threatening complications. Several arylamine drugs, such as sulfamethoxazole (SMX) and dapsone (DDS), undergo bioactivation, resulting in adduction to cellular proteins. These adducted proteins may initiate the immune response that ultimately results in a CDR. Recent studies have demonstrated that normal human epidermal keratinocytes (NHEKs) can bioactivate these drugs, resulting in protein haptenation. We sought to identify the enzyme(s) responsible for this bioactivation in NHEKs. Using immunofluorescence confocal microscopy and an adduct-specific enzyme-linked immunosorbent assay (ELISA), we found that N-acetylation of the primary amine of SMX and DDS markedly reduced the level of protein haptenation in NHEKs. Detection of mRNA and/or protein confirmed the presence of CYP3A4, CYP3A5, and CYP2E1 in NHEKs. In contrast, although a faint band suggestive of CYP2C9 protein was detected in one NHEK sample, a CYP2C9 message was not detectable. We also examined the ability of chemical inhibitors of cytochromes P450 (aminobenzotriazole and 1-dichloroethylene) and cyclooxygenase (indomethacin) to reduce protein haptenation when NHEKs were incubated with SMX or DDS by either confocal microscopy or ELISA. These inhibitors did not significantly attenuate protein adduction with either SMX or DDS, indicating that cytochromes P450 and cyclooxygenase do not play important roles in the bioactivation of these xenobiotics in NHEKs and thus suggesting the importance of other enzymes in these cells.
authors.affiliation: Division of Pharmaceutics, College of Pharmacy, University of Iowa, Iowa City, Iowa, USA.
authors.forename: Piyush M
authors.initials: PM
authors.lastname: Vyas
authors.forename: Sanjoy
authors.initials: S
authors.lastname: Roychowdhury
authors.forename: Farah D
authors.initials: FD
authors.lastname: Khan
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Prisinzano
authors.forename: Jatinder
authors.initials: J
authors.lastname: Lamba
authors.forename: Erin G
authors.initials: EG
authors.lastname: Schuetz
authors.forename: Joyce
authors.initials: J
authors.lastname: Blaisdell
authors.forename: Joyce A
authors.initials: JA
authors.lastname: Goldstein
authors.forename: Kimber L
authors.initials: KL
authors.lastname: Munson
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Hines
authors.forename: Craig K
authors.initials: CK
authors.lastname: Svensson
mesh_terms: D000107:Acetylation; D002478:Cells, Cultured; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology*; D003622:Dapsone / Q000009:adverse effects / Q000378:metabolism*; D006241:Haptens / Q000378:metabolism*; D006801:Humans; D015603:Keratinocytes / Q000187:drug effects / Q000378:metabolism*; D013420:Sulfamethoxazole / Q000009:adverse effects / Q000378:metabolism*
chemical_list: D006241:Haptens; D003622:Dapsone; D003577:Cytochrome P-450 Enzyme System; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D013420:Sulfamethoxazole